{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:16:02Z","timestamp":1772151362868,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Tislelizumab, a programmed cell death-1 inhibitor approved for multiple malignancies, may induce Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN)\u2014a rare but potentially fatal severe drug eruption\u2014and early effective intervention is pivotal for reducing SJS\/TEN-related mortality. We describe an elderly male with hepatic malignancy who developed progressive SJS\/TEN, involving over 80% of his total body surface area, after his first tislelizumab infusion. Conventional treatment with systemic corticosteroids combined with intravenous immunoglobulin was ineffective in halting disease progression. Subsequently, adjunctive therapy with a tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitor and hemoperfusion was initiated, leading to the patient\u2019s eventual recovery. Managing SJS\/TEN in patients with advanced malignancies poses substantial challenges, given the life-threatening nature of both entities. To our knowledge, this is the first reported case of using a TNF-\u03b1 inhibitor for treating tislelizumab-induced SJS\/TEN. This case highlights a novel, cost-effective, and well-tolerated therapeutic strategy that yielded favorable outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1689877","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:37:47Z","timestamp":1763534267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Stevens-Johnson syndrome\/toxic epidermal necrolysis induced by tislelizumab: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Hongtao","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xifang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junkai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-024-00889-6","article-title":"Update on stevens\u2013johnson syndrome and toxic epidermal necrolysis: diagnosis and management","volume":"25","author":"Shah","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890701753664","article-title":"Stevens-Johnson syndrome: Pathogenesis, diagnosis, and management","volume":"40","author":"Hazin","year":"2009","journal-title":"Ann Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00825-2","article-title":"Mechanisms of severe cutaneous adverse reactions: recent advances","volume":"42","author":"Bell\u00f3n","year":"2019","journal-title":"Drug Safety."},{"key":"B4","volume-title":"L. Tislelizumab injection package insert","year":"2023"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1522525","article-title":"Case report: Toxic epidermal necrolysis induced by tislelizumab in a patient with esophageal squamous cell carcinoma","volume":"11","author":"Wu","year":"2024","journal-title":"Front Med-Lausanne."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0477","article-title":"Steven-johnson syndrome\/toxic epidermal necrolysis is associated with PD-1\/PD-L1 inhibitors usage: A case series","volume":"2024","author":"Cao","year":"2024","journal-title":"Brit J Hosp Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1097\/MJT.0000000000001682","article-title":"Tislelizumab-induced toxic epidermal necrolysis-like cutaneous adverse reaction: rare complication of immune checkpoint inhibitor therapy","volume":"31","author":"Yang","year":"2024","journal-title":"Am J Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15150","article-title":"Toxic epidermal necrolysis post apalutamide with preceding tislelizumab administration in a patient with two cancers","volume":"21","author":"Wu","year":"2023","journal-title":"JDDG: J der Deutschen Dermatologischen Gesellschaft."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2174\/0115748863297885240604111018","article-title":"Treatment of tislelizumab-induced toxic epidermal necrolysis and agranulocytosis: A case report and literature review","volume":"20","author":"Zhou","year":"2025","journal-title":"Curr Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2023.2275028","article-title":"Literature analysis of cutaneous adverse reactions induced by tislelizumab","volume":"43","author":"Guo","year":"2024","journal-title":"Cutan Ocul Toxicol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/all.16316","article-title":"Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology","volume":"80","author":"Cadot","year":"2025","journal-title":"Allergy."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08859-0","article-title":"Current perspectives on severe drug eruption","volume":"61","author":"Zhang","year":"2021","journal-title":"Clin Rev Allerg Immu."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1596842","article-title":"Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0081","article-title":"Lichenoid dermatitis following pd-1 inhibitor-induced toxic epidermal necrolysis: A case report and literature review","volume":"15","author":"Zhang","year":"2023","journal-title":"Immunotherapy-Uk."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X231213927","article-title":"Lichenoid drug reaction after ipilimumab\/nivolumab combination therapy: A case report","volume":"11","author":"Moore","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s00403-024-03089-8","article-title":"Nivolumab-induced SJS\/TEN-like reaction","volume":"316","author":"Fazelpour","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13704","article-title":"Pembrolizumab associated Stevens\u2013Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma","volume":"63","author":"Zhang","year":"2022","journal-title":"Australas J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/bjd\/ljae321","article-title":"Recent progress in Stevens-Johnson syndrome\/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment","volume":"192","author":"Hama","year":"2024","journal-title":"Brit J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-024-00866-z","article-title":"The use of biologic agents for the treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors: A review of reported cases","volume":"25","author":"Pach","year":"2024","journal-title":"Am J Clin Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1689877\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:37:48Z","timestamp":1763534268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1689877\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2025.1689877"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1689877","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1689877"}}